United Therapeutics | UTHR - Operating Expenses


United Therapeutics reported $6.28B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Amarin USD 51.48M 113K Dec/2025
Ardelyx USD 133.3M 6.04M Jun/2026
Baxter International USD 6.5B 3.82B Sep/2026
Bayer EUR 9.92B 121M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Insmed USD 606.26M 79.46M Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Moderna USD 1.18B 223M Sep/2026
Omeros USD 59.16M 20.13M Jun/2024
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026
United Therapeutics USD 6.28B 124.3M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026